Ergebnis der Suchanfrage nach M&uuml

Inhalte

Filtern
2632 Treffer
  • 21.09.2007 – 18:20

    Helsinn Healthcare SA

    The CHMP/EMEA has confirmed that the benefit/risk profile of Nimesulide is positive

    London (ots) - Helsinn's Top Management today announced the positive outcome of the EMEA procedure, according to Article 107, initiated due to concerns over serious liver problems. The Committee for Medicinal Products for Human Use (CHMP) today confirmed Nimesulide's positive benefit/risk profile. The benefits of these medicines outweigh their risks, but there ...

  • 20.09.2007 – 08:01

    Nordex SE

    Demand for Nordex from China is still growing

    Winners in the tender for 71 megawatt turbines / order worth EUR 73 million ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. industry/Order intake Norderstedt (euro adhoc) - Nordex has again proved successful in tenders for wind parks in China. The company will be supplying 38 N60/1300 kW turbines for the Zhangwu Julonghu project (49.4 MW) and 33 ...

  • 19.09.2007 – 14:10

    IsoTis OrthoBiologics

    IsoTis - Integra Merger

    Irvine, California (ots/PRNewswire) - - Leading Proxy Advisor Recommends Shareholders Support Merger IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that Institutional Shareholder Services, ISS, a leading proxy advisor, recommends shareholders support the merger of IsoTis and Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra"). For every M&A analysis, ISS reviews publicly available information and evaluates ...

  • 13.09.2007 – 09:32

    Roche Pharmaceuticals

    Roche Launches Another Large Study With PEGASYS Plus COPEGUS

    Basel, Switzerland (ots/PRNewswire) - - PROPHESYS Will Identify Factors That Influence Early Response to Treatment Roche announces the start of a large multinational observational study, called PROPHESYS, in patients with hepatitis C (HCV). This international cohort study will evaluate the important factors that give hepatitis C patients the best chance of treatment success with PEGASYS(R) (peginterferon ...

  • 12.09.2007 – 14:28

    Atmel Corporation

    Atmel's AT90SC256144RCFT Secure Microcontroller Qualified by FIME for ePassport Applications

    Rousset, France (ots/PRNewswire) - Atmel(R) Corporation (Nasdaq: ATML) announced today that FIME, an external and independent third party laboratory, has certified that Atmel's AT90SC256144RCFT secure microcontroller is compliant with ICAO (International Civil Aviation Organization) and ISO14443 specifications (contactless interface for smart cards). The ...